Information Provided By:
Fly News Breaks for April 8, 2015
MDVN
Apr 8, 2015 | 07:22 EDT
Canaccord raised its price target on Medivation to $180 from $132 given the recent positive data from its STRIVE trial. The firm also sees a large market for Xtandi, with a slow ramp beginning this year but peaking with an 18% market share by 2020. Canaccord reiterated its Buy rating on Medivation shares.
News For MDVN From the Last 2 Days
There are no results for your query MDVN